IAVI V002

Phase:
II
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
Kenya;Rwanda;Uganda;Zambia
Volunteers:
0

A randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine followed by recombinant, multiclade HIV-1 adenoviral vector vaccine.